Navigation Links
ACS Expands National Dental Outreach Program to Dallas
Date:3/27/2008

Elementary school children to benefit from free dental screening

DALLAS, March 27 /PRNewswire-FirstCall/ -- As part of its nationwide Dental Outreach Initiative, Affiliated Computer Services, Inc. (ACS) will sponsor free dental education and screening for children in Dallas on Friday, March 28. The event will be held for pupils at Nancy J. Cochran Elementary School, 6000 Keeneland Parkway in Dallas, starting at 9:00 a.m.

The program, conducted in partnership with local volunteer dental professionals, provides free dental education and screenings to underserved children. ACS extended the initiative to Texas in September 2007 with a goal of educating and screening 2,000 children throughout the state. The program serves children in six states and the District of Columbia. Since the initiative was launched in 2004, more than 25,000 children have received dental education.

"With our deep roots in Texas, we are concerned about the health and well- being of our state's neediest children," said Kevin Kyser, ACS chief financial officer. "As a responsible corporate citizen, ACS is committed to helping Texans build and improve their lives. Working with our partners through the Dental Outreach is an opportunity to teach children habits that will profoundly benefit their lives for years to come."

The ACS Dental Outreach Initiative provides free dental screenings and education seminars on dental hygiene by licensed professionals. To reinforce what they learn during the seminars, students receive a gift bag containing a toothbrush, toothpaste, and dental education material. In addition, children receive a screening evaluation and a recommendation report to share with their parents or guardian.

"The ACS Dental Outreach Initiative is our way of reaching into communities throughout the state to help Texas children have not only healthy smiles, but healthy futures as well," said Kyser.

For many children, the ACS Dental Initiative scre
'/>"/>

SOURCE Affiliated Computer Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
2. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
3. Murad Expands International Presence With Appointment of Danny Guez
4. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
5. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
6. Eating Disorders Program at Lucile Packard Childrens Hospital Expands to Include Young Adults
7. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
8. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
9. Millennium Expands IBD Franchise with Addition of New Development Candidate
10. inVentiv Clinical Expands Operations to Emerging Latin American Region
11. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4Studying cancer in pet dogs to find new treatments for human patients 59325 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8